1. Home
  2. PHAR vs MAX Comparison

PHAR vs MAX Comparison

Compare PHAR & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$15.27

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$7.38

Market Cap

722.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
MAX
Founded
1988
2014
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
722.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PHAR
MAX
Price
$15.27
$7.38
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$38.00
$17.00
AVG Volume (30 Days)
37.8K
814.4K
Earning Date
03-12-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$362,274,000.00
$1,123,093,000.00
Revenue This Year
$25.19
$30.80
Revenue Next Year
$4.47
$8.49
P/E Ratio
$2,766.89
N/A
Revenue Growth
26.78
64.86
52 Week Low
$7.50
$7.25
52 Week High
$21.34
$13.92

Technical Indicators

Market Signals
Indicator
PHAR
MAX
Relative Strength Index (RSI) 36.80 16.27
Support Level $15.26 $7.25
Resistance Level $16.48 $9.61
Average True Range (ATR) 0.66 0.55
MACD -0.43 -0.21
Stochastic Oscillator 4.27 1.87

Price Performance

Historical Comparison
PHAR
MAX

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

Share on Social Networks: